Chronic Neutrophilic Leukemia
Associated Genetic Biomarkers
NCI Definition: A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis. There is no detectable Philadelphia chromosome or BCR/ABL fusion gene. 
Chronic neutrophilic leukemias most frequently harbor alterations in RUNX1, TET2, SRSF2, IDH1, and GATA2 .
RUNX1 c.170-c.1439 Missense, RUNX1 Mutation, TET2 c.3400-c.4331 Missense, TET2 c.3310-c.4434 Missense, and TET2 Mutation are the most common alterations in chronic neutrophilic leukemia .
There are 2 clinical trials for chronic neutrophilic leukemia, of which 1 is open and 1 is completed or closed. Of the trials that contain chronic neutrophilic leukemia as an inclusion criterion, 2 are phase 2 (1 open).
CSF3R is the most frequent gene inclusion criterion for chronic neutrophilic leukemia clinical trials .
Ruxolitinib is the most common intervention in chronic neutrophilic leukemia clinical trials.
Significant Genes in Chronic Neutrophilic Leukemia
CSF3R is altered in 25.0% of chronic neutrophilic leukemia patients .
CSF3R is an inclusion eligibility criterion in 1 clinical trial for chronic neutrophilic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CSF3R status and chronic neutrophilic leukemia as inclusion criteria, 1 is phase 2 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.